Vancouver Sun

Painkiller may be linked to ADHD: study

- LINDA CARROLL

Babies born to women who used acetaminop­hen late in pregnancy may be at increased risk of ADHD and autism spectrum disorder, a new study suggests.

After examining stored blood samples from babies’ umbilical cords, researcher­s determined that the risks of ADHD and autism were significan­tly increased in children whose blood had high levels of acetaminop­hen breakdown products, according to a report in JAMA Psychiatry.

“Our findings corroborat­e previous studies that were based on maternal self-report of acetaminop­hen use and they warrant additional investigat­ions,” said Dr. Xiaobin Wang, a professor of pediatrics at the Johns Hopkins School of Medicine in Baltimore and director of the Center on Early Life Origins of Disease at the Johns Hopkins Bloomberg School of Public Health. This study, “provides objective evidence of fetal exposure to acetaminop­hen in utero.”

Earlier research showed that acetaminop­hen can cross through the placenta, Wang noted. Because the metabolite­s, or breakdown products, of the drug appear to linger for nearly two days, researcher­s are able to get an estimate of maternal acetaminop­hen use in the hours before delivery.

For a window on the possible impact of acetaminop­hen exposure on babies’ risks of developing certain neurodevel­opmental disorders, the researcher­s turned to data from the Boston Birth Cohort.

Wang and her colleagues focused on 996 mother-infant pairs, for whom there was sufficient cord blood in the samples for an analysis of acetaminop­hen metabolite­s.

When they compared children with cord blood containing the highest levels of acetaminop­hen metabolite­s to those with the lowest levels, they found a significan­t associatio­n between acetaminop­hen metabolite levels and neurodevel­opmental disorders. Those at the highest levels were 2.86 times more likely than those at the lowest to have been diagnosed with ADHD and 3.62 times more likely to have an ASD diagnosis.

Because metabolite levels were measured only around the time of birth, the researcher­s can’t say anything about how often the mothers took the drug or at which points during pregnancy, Wang said.

“Our study opened inquiry for further investigat­ion,” she added.

Dr. Hyagriv Simhan isn’t ready to tell his pregnant patients to stop using acetaminop­hen. “First, the acetaminop­hen metabolite levels in the cord blood only reflects acetaminop­hen use around the time of delivery and doesn’t reflect exposure to acetaminop­hen during other points in the pregnancy,” Simhan, executive vice-chair of obstetrica­l services at UPMC Magee-womens Hospital in Pittsburgh, Pa., said.

Beyond that, Simhan said, “In the grand scheme, the effect described in this study is not a large one.”

Newspapers in English

Newspapers from Canada